LobbyingMetacel Pharmaceuticals lobbying by quarter
Metacel Pharmaceuticals's latest lobbying report covers Q4 2023, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medical/Disease Research/Clinical Labs.
Metacel Pharmaceuticals
- Latest quarter
- No record
- Q2 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $30K | 1 |
| Q1 2023 | $0 | 1 |
| Q2 2023 | $0 | 1 |
| Q3 2023 | $0 | 1 |
| Q4 2023 | $0 | 1 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
Policy issues the reports name
- Health issues2 reports
- Medical research and clinical labs2 reports
- Pharmacy2 reports
A report that names several issues counts once for each.
Who was lobbied
- Food & Drug Administration (FDA)2 reports
- HOUSE OF REPRESENTATIVES2 reports
- SENATE2 reports
Firms it paid
| Firm | ||
|---|---|---|
| Buchanan Ingersoll & Rooney PC | $30K | 5 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/01/22for Q4 2023 | Buchanan Ingersoll & Rooney PC | Under $5,000 |
| 23/10/20for Q3 2023 | Buchanan Ingersoll & Rooney PC | Under $5,000 |
| 23/07/19for Q2 2023 | Buchanan Ingersoll & Rooney PC | Under $5,000 |
| 23/04/20for Q1 2023 | Buchanan Ingersoll & Rooney PC | Under $5,000 |
| 23/01/13for Q4 2022 | Buchanan Ingersoll & Rooney PC | $30K |